Medifast (MED) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue declined 43.1% year-over-year to $168.6M, driven by a 36.2% drop in active earning OPTAVIA Coaches and lower productivity, but gross margin improved and the company is transforming to address the expanding GLP-1 medication market through partnerships, new product development, and a multi-channel approach.

• Net loss for Q2 2024 was $8.2M, or $0.75 per diluted share, while non-GAAP adjusted net income was $10.1M, or $0.92 per share.

• The company is debt-free with $163.5M–$164M in cash and investments as of June 30, 2024, and is investing in marketing and LifeMD collaboration to broaden its customer base and address GLP-1 adoption.

• Enhanced digital tools, personalized coaching, and a brand refresh aim to improve customer engagement and retention.

Financial highlights

• Q2 2024 revenue was $168.6M–$169M, with gross profit of $123.4M and gross margin improved to 73.2% (up 210 bps); non-GAAP adjusted gross margin was 74.8% (up 370 bps).

• Net loss was $8.2M ($0.75 per diluted share); adjusted net income was $10.1M ($0.92 per share).

• SG&A expenses fell 23.7% to $131.3M, but as a percent of revenue increased to 77.9%.

• Non-GAAP adjusted income from operations was $12.2M (7.3% of revenue), down 68.4%.

• Cash and investments totaled $163.5M–$164M at quarter-end, with no debt.

Outlook and guidance

• Q3 2024 revenue expected between $125M and $145M, with diluted loss per share projected between $0.05 and $0.70, excluding certain LifeMD-related costs and investment gains/losses.

• Full-year marketing spend revised to $25M, with $10M spent through June, aligning with product launch timing.

• Management expects continued short-term pressure on customer acquisition and Coach count due to GLP-1 competition, but anticipates top-line improvement from new initiatives starting late 2024 and into 2025.